Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc and changed its name to Unity Biotechnology, Inc in January 2015.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees106
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions
What is Unity Biotechnology's stock symbol?
Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."
How were Unity Biotechnology's earnings last quarter?
Unity Biotechnology Inc (NASDAQ:UBX) posted its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.10. View Unity Biotechnology's Earnings History.
When is Unity Biotechnology's next earnings date?
What price target have analysts set for UBX?
3 brokerages have issued 12-month price objectives for Unity Biotechnology's shares. Their predictions range from $14.00 to $21.00. On average, they anticipate Unity Biotechnology's share price to reach $17.50 in the next twelve months. This suggests a possible upside of 147.9% from the stock's current price. View Analyst Price Targets for Unity Biotechnology.
What is the consensus analysts' recommendation for Unity Biotechnology?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unity Biotechnology.
What are Wall Street analysts saying about Unity Biotechnology stock?
Here are some recent quotes from research analysts about Unity Biotechnology stock:
- 1. According to Zacks Investment Research, "UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company's product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. " (10/12/2019)
- 2. Cantor Fitzgerald analysts commented, ": We are initiating coverage on UNITY Overweight rating and 12-month PT of $21. UNITY is making progress on treatments that could extend healthspan, a longer disease-free state, by targeting indications that are associated with aging. UNITY focuses on eliminating senescent cells, the precursors to disease progression. Lead product UBX0101 is in Phase 1 development for osteoarthritis (OA), with proof-of-concept data expected in 2Q19." (3/6/2019)
Has Unity Biotechnology been receiving favorable news coverage?
News coverage about UBX stock has trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Unity Biotechnology earned a media sentiment score of -3.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Unity Biotechnology.
Are investors shorting Unity Biotechnology?
Unity Biotechnology saw a increase in short interest during the month of September. As of September 15th, there was short interest totalling 5,150,000 shares, an increase of 5.1% from the August 15th total of 4,900,000 shares. Based on an average daily trading volume, of 299,700 shares, the short-interest ratio is currently 17.2 days. Currently, 24.2% of the company's stock are sold short. View Unity Biotechnology's Current Options Chain.
Who are some of Unity Biotechnology's key competitors?
Some companies that are related to Unity Biotechnology include Audentes Therapeutics (BOLD), Summerset Group (SNZ), National HealthCare (NHC), Concordia International (CXR), Veracyte (VCYT), BELLUS Health (BLUSF), STAAR Surgical (STAA), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), Zymeworks (ZYME), Turning Point Therapeutics (TPTX), CareDx (CDNA), Tabula Rasa HealthCare (TRHC), Health Catalyst (HCAT) and Aphria (APHA).
What other stocks do shareholders of Unity Biotechnology own?
Who are Unity Biotechnology's key executives?
Unity Biotechnology's management team includes the folowing people:
- Mr. Keith R. Leonard Jr., Exec. Chairman & CEO (Age 57)
- Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 51)
- Mr. Robert C. Goeltz II, Chief Financial Officer (Age 46)
- Dr. Jan M. van Deursen, Founder
- Dr. Judith Campisi, Founder
When did Unity Biotechnology IPO?
(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.
How do I buy shares of Unity Biotechnology?
Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Unity Biotechnology's stock price today?
One share of UBX stock can currently be purchased for approximately $7.06.
How big of a company is Unity Biotechnology?
MarketBeat Community Rating for Unity Biotechnology (NASDAQ UBX)
MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote "Outperform" if you believe UBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
